- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
The Alpha- Antitrypsin Deficiency Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Alpha- Antitrypsin Deficiency Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Clinic accounting for % of the Alpha- Antitrypsin Deficiency Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While CT-2009 segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Alpha- Antitrypsin Deficiency Treatment include Adverum Biotechnologies, Inc., Alnylam Pharmaceuticals, Inc., Applied Genetic Technologies Corporation, Arrowhead Pharmaceuticals, Inc., and Carolus Therapeutics, Inc., etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Alpha- Antitrypsin Deficiency Treatment market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
CT-2009
POL-6014
ARO-AAT
ALNAAT-02
Others
Market segment by Application, can be divided into
Clinic
Hospital
Others
Market segment by players, this report covers
Adverum Biotechnologies, Inc.
Alnylam Pharmaceuticals, Inc.
Applied Genetic Technologies Corporation
Arrowhead Pharmaceuticals, Inc.
Carolus Therapeutics, Inc.
Cevec Pharmaceuticals GmbH
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Editas Medicine, Inc.
Grifols, S.A.
Inhibrx
Intellia Therapeutics, Inc.
International Stem Cell Corporation
Ionis Pharmaceuticals, Inc.
Kamada Ltd.
Polyphor Ltd.
ProMetic Life Sciences Inc.
rEVO Biologics, Inc.
Sangamo BioSciences, Inc.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Alpha- Antitrypsin Deficiency Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Alpha- Antitrypsin Deficiency Treatment, with revenue, gross margin and global market share of Alpha- Antitrypsin Deficiency Treatment from 2019 to 2022.
Chapter 3, the Alpha- Antitrypsin Deficiency Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Alpha- Antitrypsin Deficiency Treatment market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Alpha- Antitrypsin Deficiency Treatment research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Alpha- Antitrypsin Deficiency Treatment
1.2 Classification of Alpha- Antitrypsin Deficiency Treatment by Type
1.2.1 Overview: Global Alpha- Antitrypsin Deficiency Treatment Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Type in 2021
1.2.3 CT-2009
1.2.4 POL-6014
1.2.5 ARO-AAT
1.2.6 ALNAAT-02
1.2.7 Others
1.3 Global Alpha- Antitrypsin Deficiency Treatment Market by Application
1.3.1 Overview: Global Alpha- Antitrypsin Deficiency Treatment Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Alpha- Antitrypsin Deficiency Treatment Market Size & Forecast
1.5 Global Alpha- Antitrypsin Deficiency Treatment Market Size and Forecast by Region
1.5.1 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Alpha- Antitrypsin Deficiency Treatment Market Size by Region, (2017-2022)
1.5.3 North America Alpha- Antitrypsin Deficiency Treatment Market Size and Prospect (2017-2028)
1.5.4 Europe Alpha- Antitrypsin Deficiency Treatment Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size and Prospect (2017-2028)
1.5.6 South America Alpha- Antitrypsin Deficiency Treatment Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Alpha- Antitrypsin Deficiency Treatment Market Drivers
1.6.2 Alpha- Antitrypsin Deficiency Treatment Market Restraints
1.6.3 Alpha- Antitrypsin Deficiency Treatment Trends Analysis
2 Company Profiles
2.1 Adverum Biotechnologies, Inc.
2.1.1 Adverum Biotechnologies, Inc. Details
2.1.2 Adverum Biotechnologies, Inc. Major Business
2.1.3 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
2.1.4 Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Adverum Biotechnologies, Inc. Recent Developments and Future Plans
2.2 Alnylam Pharmaceuticals, Inc.
2.2.1 Alnylam Pharmaceuticals, Inc. Details
2.2.2 Alnylam Pharmaceuticals, Inc. Major Business
2.2.3 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
2.2.4 Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Alnylam Pharmaceuticals, Inc. Recent Developments and Future Plans
2.3 Applied Genetic Technologies Corporation
2.3.1 Applied Genetic Technologies Corporation Details
2.3.2 Applied Genetic Technologies Corporation Major Business
2.3.3 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Product and Solutions
2.3.4 Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Applied Genetic Technologies Corporation Recent Developments and Future Plans
2.4 Arrowhead Pharmaceuticals, Inc.
2.4.1 Arrowhead Pharmaceuticals, Inc. Details
2.4.2 Arrowhead Pharmaceuticals, Inc. Major Business
2.4.3 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
2.4.4 Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Arrowhead Pharmaceuticals, Inc. Recent Developments and Future Plans
2.5 Carolus Therapeutics, Inc.
2.5.1 Carolus Therapeutics, Inc. Details
2.5.2 Carolus Therapeutics, Inc. Major Business
2.5.3 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
2.5.4 Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Carolus Therapeutics, Inc. Recent Developments and Future Plans
2.6 Cevec Pharmaceuticals GmbH
2.6.1 Cevec Pharmaceuticals GmbH Details
2.6.2 Cevec Pharmaceuticals GmbH Major Business
2.6.3 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Product and Solutions
2.6.4 Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Cevec Pharmaceuticals GmbH Recent Developments and Future Plans
2.7 Dicerna Pharmaceuticals, Inc.
2.7.1 Dicerna Pharmaceuticals, Inc. Details
2.7.2 Dicerna Pharmaceuticals, Inc. Major Business
2.7.3 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
2.7.4 Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Dicerna Pharmaceuticals, Inc. Recent Developments and Future Plans
2.8 Digna Biotech, S.L.
2.8.1 Digna Biotech, S.L. Details
2.8.2 Digna Biotech, S.L. Major Business
2.8.3 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
2.8.4 Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Digna Biotech, S.L. Recent Developments and Future Plans
2.9 Editas Medicine, Inc.
2.9.1 Editas Medicine, Inc. Details
2.9.2 Editas Medicine, Inc. Major Business
2.9.3 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
2.9.4 Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Editas Medicine, Inc. Recent Developments and Future Plans
2.10 Grifols, S.A.
2.10.1 Grifols, S.A. Details
2.10.2 Grifols, S.A. Major Business
2.10.3 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
2.10.4 Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Grifols, S.A. Recent Developments and Future Plans
2.11 Inhibrx
2.11.1 Inhibrx Details
2.11.2 Inhibrx Major Business
2.11.3 Inhibrx Alpha- Antitrypsin Deficiency Treatment Product and Solutions
2.11.4 Inhibrx Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Inhibrx Recent Developments and Future Plans
2.12 Intellia Therapeutics, Inc.
2.12.1 Intellia Therapeutics, Inc. Details
2.12.2 Intellia Therapeutics, Inc. Major Business
2.12.3 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
2.12.4 Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Intellia Therapeutics, Inc. Recent Developments and Future Plans
2.13 International Stem Cell Corporation
2.13.1 International Stem Cell Corporation Details
2.13.2 International Stem Cell Corporation Major Business
2.13.3 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Product and Solutions
2.13.4 International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 International Stem Cell Corporation Recent Developments and Future Plans
2.14 Ionis Pharmaceuticals, Inc.
2.14.1 Ionis Pharmaceuticals, Inc. Details
2.14.2 Ionis Pharmaceuticals, Inc. Major Business
2.14.3 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
2.14.4 Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 Ionis Pharmaceuticals, Inc. Recent Developments and Future Plans
2.15 Kamada Ltd.
2.15.1 Kamada Ltd. Details
2.15.2 Kamada Ltd. Major Business
2.15.3 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
2.15.4 Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15.5 Kamada Ltd. Recent Developments and Future Plans
2.16 Polyphor Ltd.
2.16.1 Polyphor Ltd. Details
2.16.2 Polyphor Ltd. Major Business
2.16.3 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
2.16.4 Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16.5 Polyphor Ltd. Recent Developments and Future Plans
2.17 ProMetic Life Sciences Inc.
2.17.1 ProMetic Life Sciences Inc. Details
2.17.2 ProMetic Life Sciences Inc. Major Business
2.17.3 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
2.17.4 ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17.5 ProMetic Life Sciences Inc. Recent Developments and Future Plans
2.18 rEVO Biologics, Inc.
2.18.1 rEVO Biologics, Inc. Details
2.18.2 rEVO Biologics, Inc. Major Business
2.18.3 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
2.18.4 rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18.5 rEVO Biologics, Inc. Recent Developments and Future Plans
2.19 Sangamo BioSciences, Inc.
2.19.1 Sangamo BioSciences, Inc. Details
2.19.2 Sangamo BioSciences, Inc. Major Business
2.19.3 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
2.19.4 Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19.5 Sangamo BioSciences, Inc. Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Alpha- Antitrypsin Deficiency Treatment Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Alpha- Antitrypsin Deficiency Treatment Players Market Share in 2021
3.2.2 Top 10 Alpha- Antitrypsin Deficiency Treatment Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Alpha- Antitrypsin Deficiency Treatment Players Head Office, Products and Services Provided
3.4 Alpha- Antitrypsin Deficiency Treatment Mergers & Acquisitions
3.5 Alpha- Antitrypsin Deficiency Treatment New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Alpha- Antitrypsin Deficiency Treatment Revenue and Market Share by Type (2017-2022)
4.2 Global Alpha- Antitrypsin Deficiency Treatment Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Application (2017-2022)
5.2 Global Alpha- Antitrypsin Deficiency Treatment Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Alpha- Antitrypsin Deficiency Treatment Revenue by Type (2017-2028)
6.2 North America Alpha- Antitrypsin Deficiency Treatment Revenue by Application (2017-2028)
6.3 North America Alpha- Antitrypsin Deficiency Treatment Market Size by Country
6.3.1 North America Alpha- Antitrypsin Deficiency Treatment Revenue by Country (2017-2028)
6.3.2 United States Alpha- Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
6.3.3 Canada Alpha- Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
6.3.4 Mexico Alpha- Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Alpha- Antitrypsin Deficiency Treatment Revenue by Type (2017-2028)
7.2 Europe Alpha- Antitrypsin Deficiency Treatment Revenue by Application (2017-2028)
7.3 Europe Alpha- Antitrypsin Deficiency Treatment Market Size by Country
7.3.1 Europe Alpha- Antitrypsin Deficiency Treatment Revenue by Country (2017-2028)
7.3.2 Germany Alpha- Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
7.3.3 France Alpha- Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Alpha- Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
7.3.5 Russia Alpha- Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
7.3.6 Italy Alpha- Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Revenue by Type (2017-2028)
8.2 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Revenue by Application (2017-2028)
8.3 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Market Size by Region
8.3.1 Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Revenue by Region (2017-2028)
8.3.2 China Alpha- Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
8.3.3 Japan Alpha- Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
8.3.4 South Korea Alpha- Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
8.3.5 India Alpha- Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Alpha- Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
8.3.7 Australia Alpha- Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Alpha- Antitrypsin Deficiency Treatment Revenue by Type (2017-2028)
9.2 South America Alpha- Antitrypsin Deficiency Treatment Revenue by Application (2017-2028)
9.3 South America Alpha- Antitrypsin Deficiency Treatment Market Size by Country
9.3.1 South America Alpha- Antitrypsin Deficiency Treatment Revenue by Country (2017-2028)
9.3.2 Brazil Alpha- Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
9.3.3 Argentina Alpha- Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Revenue by Type (2017-2028)
10.2 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Revenue by Application (2017-2028)
10.3 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Market Size by Country
10.3.1 Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Revenue by Country (2017-2028)
10.3.2 Turkey Alpha- Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Alpha- Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
10.3.4 UAE Alpha- Antitrypsin Deficiency Treatment Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Alpha- Antitrypsin Deficiency Treatment Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Alpha- Antitrypsin Deficiency Treatment Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Alpha- Antitrypsin Deficiency Treatment Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million) by Region (2017-2022)
Table 5. Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Region (2023-2028)
Table 6. Adverum Biotechnologies, Inc. Corporate Information, Head Office, and Major Competitors
Table 7. Adverum Biotechnologies, Inc. Major Business
Table 8. Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
Table 9. Adverum Biotechnologies, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Alnylam Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
Table 11. Alnylam Pharmaceuticals, Inc. Major Business
Table 12. Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
Table 13. Alnylam Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Applied Genetic Technologies Corporation Corporate Information, Head Office, and Major Competitors
Table 15. Applied Genetic Technologies Corporation Major Business
Table 16. Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Product and Solutions
Table 17. Applied Genetic Technologies Corporation Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Arrowhead Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
Table 19. Arrowhead Pharmaceuticals, Inc. Major Business
Table 20. Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
Table 21. Arrowhead Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Carolus Therapeutics, Inc. Corporate Information, Head Office, and Major Competitors
Table 23. Carolus Therapeutics, Inc. Major Business
Table 24. Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
Table 25. Carolus Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Cevec Pharmaceuticals GmbH Corporate Information, Head Office, and Major Competitors
Table 27. Cevec Pharmaceuticals GmbH Major Business
Table 28. Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Product and Solutions
Table 29. Cevec Pharmaceuticals GmbH Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Dicerna Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
Table 31. Dicerna Pharmaceuticals, Inc. Major Business
Table 32. Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
Table 33. Dicerna Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Digna Biotech, S.L. Corporate Information, Head Office, and Major Competitors
Table 35. Digna Biotech, S.L. Major Business
Table 36. Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
Table 37. Digna Biotech, S.L. Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Editas Medicine, Inc. Corporate Information, Head Office, and Major Competitors
Table 39. Editas Medicine, Inc. Major Business
Table 40. Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
Table 41. Editas Medicine, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Grifols, S.A. Corporate Information, Head Office, and Major Competitors
Table 43. Grifols, S.A. Major Business
Table 44. Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
Table 45. Grifols, S.A. Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Inhibrx Corporate Information, Head Office, and Major Competitors
Table 47. Inhibrx Major Business
Table 48. Inhibrx Alpha- Antitrypsin Deficiency Treatment Product and Solutions
Table 49. Inhibrx Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Intellia Therapeutics, Inc. Corporate Information, Head Office, and Major Competitors
Table 51. Intellia Therapeutics, Inc. Major Business
Table 52. Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
Table 53. Intellia Therapeutics, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. International Stem Cell Corporation Corporate Information, Head Office, and Major Competitors
Table 55. International Stem Cell Corporation Major Business
Table 56. International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Product and Solutions
Table 57. International Stem Cell Corporation Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. Ionis Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
Table 59. Ionis Pharmaceuticals, Inc. Major Business
Table 60. Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
Table 61. Ionis Pharmaceuticals, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. Kamada Ltd. Corporate Information, Head Office, and Major Competitors
Table 63. Kamada Ltd. Major Business
Table 64. Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
Table 65. Kamada Ltd. Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 66. Polyphor Ltd. Corporate Information, Head Office, and Major Competitors
Table 67. Polyphor Ltd. Major Business
Table 68. Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
Table 69. Polyphor Ltd. Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 70. ProMetic Life Sciences Inc. Corporate Information, Head Office, and Major Competitors
Table 71. ProMetic Life Sciences Inc. Major Business
Table 72. ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
Table 73. ProMetic Life Sciences Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 74. rEVO Biologics, Inc. Corporate Information, Head Office, and Major Competitors
Table 75. rEVO Biologics, Inc. Major Business
Table 76. rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
Table 77. rEVO Biologics, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 78. Sangamo BioSciences, Inc. Corporate Information, Head Office, and Major Competitors
Table 79. Sangamo BioSciences, Inc. Major Business
Table 80. Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Product and Solutions
Table 81. Sangamo BioSciences, Inc. Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 82. Global Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 83. Global Alpha- Antitrypsin Deficiency Treatment Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 84. Breakdown of Alpha- Antitrypsin Deficiency Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 85. Alpha- Antitrypsin Deficiency Treatment Players Head Office, Products and Services Provided
Table 86. Alpha- Antitrypsin Deficiency Treatment Mergers & Acquisitions in the Past Five Years
Table 87. Alpha- Antitrypsin Deficiency Treatment New Entrants and Expansion Plans
Table 88. Global Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million) by Type (2017-2022)
Table 89. Global Alpha- Antitrypsin Deficiency Treatment Revenue Share by Type (2017-2022)
Table 90. Global Alpha- Antitrypsin Deficiency Treatment Revenue Forecast by Type (2023-2028)
Table 91. Global Alpha- Antitrypsin Deficiency Treatment Revenue by Application (2017-2022)
Table 92. Global Alpha- Antitrypsin Deficiency Treatment Revenue Forecast by Application (2023-2028)
Table 93. North America Alpha- Antitrypsin Deficiency Treatment Revenue by Type (2017-2022) & (USD Million)
Table 94. North America Alpha- Antitrypsin Deficiency Treatment Revenue by Type (2023-2028) & (USD Million)
Table 95. North America Alpha- Antitrypsin Deficiency Treatment Revenue by Application (2017-2022) & (USD Million)
Table 96. North America Alpha- Antitrypsin Deficiency Treatment Revenue by Application (2023-2028) & (USD Million)
Table 97. North America Alpha- Antitrypsin Deficiency Treatment Revenue by Country (2017-2022) & (USD Million)
Table 98. North America Alpha- Antitrypsin Deficiency Treatment Revenue by Country (2023-2028) & (USD Million)
Table 99. Europe Alpha- Antitrypsin Deficiency Treatment Revenue by Type (2017-2022) & (USD Million)
Table 100. Europe Alpha- Antitrypsin Deficiency Treatment Revenue by Type (2023-2028) & (USD Million)
Table 101. Europe Alpha- Antitrypsin Deficiency Treatment Revenue by Application (2017-2022) & (USD Million)
Table 102. Europe Alpha- Antitrypsin Deficiency Treatment Revenue by Application (2023-2028) & (USD Million)
Table 103. Europe Alpha- Antitrypsin Deficiency Treatment Revenue by Country (2017-2022) & (USD Million)
Table 104. Europe Alpha- Antitrypsin Deficiency Treatment Revenue by Country (2023-2028) & (USD Million)
Table 105. Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Revenue by Type (2017-2022) & (USD Million)
Table 106. Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Revenue by Type (2023-2028) & (USD Million)
Table 107. Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Revenue by Application (2017-2022) & (USD Million)
Table 108. Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Revenue by Application (2023-2028) & (USD Million)
Table 109. Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Revenue by Region (2017-2022) & (USD Million)
Table 110. Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Revenue by Region (2023-2028) & (USD Million)
Table 111. South America Alpha- Antitrypsin Deficiency Treatment Revenue by Type (2017-2022) & (USD Million)
Table 112. South America Alpha- Antitrypsin Deficiency Treatment Revenue by Type (2023-2028) & (USD Million)
Table 113. South America Alpha- Antitrypsin Deficiency Treatment Revenue by Application (2017-2022) & (USD Million)
Table 114. South America Alpha- Antitrypsin Deficiency Treatment Revenue by Application (2023-2028) & (USD Million)
Table 115. South America Alpha- Antitrypsin Deficiency Treatment Revenue by Country (2017-2022) & (USD Million)
Table 116. South America Alpha- Antitrypsin Deficiency Treatment Revenue by Country (2023-2028) & (USD Million)
Table 117. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Revenue by Type (2017-2022) & (USD Million)
Table 118. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Revenue by Type (2023-2028) & (USD Million)
Table 119. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Revenue by Application (2017-2022) & (USD Million)
Table 120. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Revenue by Application (2023-2028) & (USD Million)
Table 121. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Revenue by Country (2017-2022) & (USD Million)
Table 122. Middle East & Africa Alpha- Antitrypsin Deficiency Treatment Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Alpha- Antitrypsin Deficiency Treatment Picture
Figure 2. Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Type in 2021
Figure 3. CT-2009
Figure 4. POL-6014
Figure 5. ARO-AAT
Figure 6. ALNAAT-02
Figure 7. Others
Figure 8. Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Application in 2021
Figure 9. Clinic Picture
Figure 10. Hospital Picture
Figure 11. Others Picture
Figure 12. Global Alpha- Antitrypsin Deficiency Treatment Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 13. Global Alpha- Antitrypsin Deficiency Treatment Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Region (2017-2028)
Figure 15. Global Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Region in 2021
Figure 16. North America Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Europe Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. South America Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Alpha- Antitrypsin Deficiency Treatment Market Drivers
Figure 22. Alpha- Antitrypsin Deficiency Treatment Market Restraints
Figure 23. Alpha- Antitrypsin Deficiency Treatment Market Trends
Figure 24. Adverum Biotechnologies, Inc. Recent Developments and Future Plans
Figure 25. Alnylam Pharmaceuticals, Inc. Recent Developments and Future Plans
Figure 26. Applied Genetic Technologies Corporation Recent Developments and Future Plans
Figure 27. Arrowhead Pharmaceuticals, Inc. Recent Developments and Future Plans
Figure 28. Carolus Therapeutics, Inc. Recent Developments and Future Plans
Figure 29. Cevec Pharmaceuticals GmbH Recent Developments and Future Plans
Figure 30. Dicerna Pharmaceuticals, Inc. Recent Developments and Future Plans
Figure 31. Digna Biotech, S.L. Recent Developments and Future Plans
Figure 32. Editas Medicine, Inc. Recent Developments and Future Plans
Figure 33. Grifols, S.A. Recent Developments and Future Plans
Figure 34. Inhibrx Recent Developments and Future Plans
Figure 35. Intellia Therapeutics, Inc. Recent Developments and Future Plans
Figure 36. International Stem Cell Corporation Recent Developments and Future Plans
Figure 37. Ionis Pharmaceuticals, Inc. Recent Developments and Future Plans
Figure 38. Kamada Ltd. Recent Developments and Future Plans
Figure 39. Polyphor Ltd. Recent Developments and Future Plans
Figure 40. ProMetic Life Sciences Inc. Recent Developments and Future Plans
Figure 41. rEVO Biologics, Inc. Recent Developments and Future Plans
Figure 42. Sangamo BioSciences, Inc. Recent Developments and Future Plans
Figure 43. Global Alpha- Antitrypsin Deficiency Treatment Revenue Share by Players in 2021
Figure 44. Alpha- Antitrypsin Deficiency Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 45. Global Top 3 Players Alpha- Antitrypsin Deficiency Treatment Revenue Market Share in 2021
Figure 46. Global Top 10 Players Alpha- Antitrypsin Deficiency Treatment Revenue Market Share in 2021
Figure 47. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 48. Global Alpha- Antitrypsin Deficiency Treatment Revenue Share by Type in 2021
Figure 49. Global Alpha- Antitrypsin Deficiency Treatment Market Share Forecast by Type (2023-2028)
Figure 50. Global Alpha- Antitrypsin Deficiency Treatment Revenue Share by Application in 2021
Figure 51. Global Alpha- Antitrypsin Deficiency Treatment Market Share Forecast by Application (2023-2028)
Figure 52. North America Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Type (2017-2028)
Figure 53. North America Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Application (2017-2028)
Figure 54. North America Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Country (2017-2028)
Figure 55. United States Alpha- Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Canada Alpha- Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Mexico Alpha- Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Europe Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Type (2017-2028)
Figure 59. Europe Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Application (2017-2028)
Figure 60. Europe Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Country (2017-2028)
Figure 61. Germany Alpha- Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. France Alpha- Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. United Kingdom Alpha- Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Russia Alpha- Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Italy Alpha- Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Type (2017-2028)
Figure 67. Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Application (2017-2028)
Figure 68. Asia-Pacific Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Region (2017-2028)
Figure 69. China Alpha- Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Japan Alpha- Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. South Korea Alpha- Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. India Alpha- Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Southeast Asia Alpha- Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Australia Alpha- Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. South America Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Type (2017-2028)
Figure 76. South America Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Application (2017-2028)
Figure 77. South America Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Country (2017-2028)
Figure 78. Brazil Alpha- Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. Argentina Alpha- Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Type (2017-2028)
Figure 81. Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Sales Market Share by Application (2017-2028)
Figure 82. Middle East and Africa Alpha- Antitrypsin Deficiency Treatment Revenue Market Share by Country (2017-2028)
Figure 83. Turkey Alpha- Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 84. Saudi Arabia Alpha- Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 85. UAE Alpha- Antitrypsin Deficiency Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 86. Methodology
Figure 87. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
